Long-term endocrine outcomes and quality of life in paediatric and young chronic myeloid leukaemia patients on tyrosine kinase inhibitor therapy: a prospective study from India.

ABSTRACT:

Background

Chronic myeloid leukaemia (CML) is rare in paediatric population, approximately 2-3% of leukaemia cases in children and 9% in adolescents. The introduction of tyrosine kinase inhibitors (TKIs) has significantly improved outcomes, but long-term use may lead to adverse endocrine effects and impact quality of life (QoL).

Methods

This prospective cross-sectional study evaluated 82 paediatric and young adult CML patients who were started on TKI therapy at <18 years of age. 71 patients were on TKI for >2 years and 11 patients were initiated on TKI during the study. Anthropometric measurements, Tanner staging, and laboratory parameters assessing endocrine function, bone health, glucose and lipid metabolism were evaluated. QoL was assessed with validated instruments.

R

SUBMITTER: Mohan R 

PROVIDER: S-EPMC12279693 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature